Xeloda plus oxaliplatin (XELOX) dramatically reduces hospital visits by over 60%

November 02, 2005

New data confirm that XELOX, a combination of Xeloda® (capecitabine) and oxaliplatin, is as safe as the current standard treatment of intravenous 5-fluorouracil/leucovorin (i.v. 5-FU/LV) in adjuvant colon cancer patients (post-surgery). Moreover, XELOX reduces the number of hospital visits by more than 60 percent compared to the current standard therapy, providing patients the freedom to live as normal a life as possible.1

"Being diagnosed with colon cancer shook me to the core. Having discussed treatment options with my doctor, I was thankful to be offered a combination treatment, including oral Xeloda, as it would mean much less time spent in hospital, so that I could get on with my life and return to work sooner," said Andy Griffin, a patient with colon cancer from the UK. "At such a difficult time in my life, it was important for me to be able to spend as much quality time with my family as possible."

In 2004, colorectal cancer was one of the leading cancers and accounted for 13 percent of all cancers.2 It is estimated that over 394,000 people die worldwide from colorectal cancer each year.3 Xeloda was approved in the EU for post-surgery treatment of colorectal cancer in April 2005. Approval was based on data (X-ACT study) that showed Xeloda to be at least equal to 5-FU/LV in terms of effectiveness with a strong trend towards improvement with fewer severe side-effects.4

"It's great to know that physicians have a new treatment option that will truly benefit their patients. This option is giving patients the freedom to live their lives while providing similar safety benefits to the current standard i.v. combination treatment in the post-surgery setting," said Professor Chris Twelves, University of Leeds and Bradford NHS Foundation Trust. "This study confirms that Xeloda, either on its own or in combination, is fast becoming the backbone of bowel cancer treatment."

Previous XELOX studies, conducted in patients where the disease has spread have shown that it is well tolerated with similar efficacy to the FOLFOX (oxaliplatin + 5-FU/LV) combination.5,6,7 XELOX is also being investigated in the largest ever Phase III clinical trial programme for the treatment of colorectal cancer, with over 4,000 patients from more than 30 countries involved.
-end-
Notes to Editors:
XELODA IN COLORECTAL CANCER

Abstract Number 617 - Initial safety findings from XELOXA: a randomized phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer1: In early Phase III safety findings, from the largest population of patients treated with XELOX to date, compared with the current standard therapy, i.v.

5-FU/LV, XELOX demonstrates benefits for the patient in terms of side-effects:
  • XELOX led to less myelosuppression (reduced production of red and white blood cells and platelets) and stomatitis (mouth inflammation / ulcers)

    Presented at ECCO on Wednesday, 2 November, 11.30 CET (poster discussion)

    About XELOX:
    An abbreviation for a type of combination chemotherapy used to treat colorectal cancer; it contains Xeloda (capecitabine) and oxaliplatin.

    About Xeloda:
    Xeloda is licensed in more than 90 countries worldwide including the EU, USA, Japan, Australia and Canada.

    Roche received marketing authorisation for Xeloda as a first-line monotherapy (by itself) in the treatment of metastatic colorectal cancer (colorectal cancer that has spread to other parts of the body) in most countries (including the EU and USA) in 2001. Xeloda has also been approved by the European Medicines Agency (EMEA) and U.S. Food and Drug Administration (FDA) for adjuvant (post-surgery) treatment of colon cancer in March and June 2005, respectively.

    Xeloda is licensed in combination with Taxotere® (docetaxel) in women with metastatic breast cancer (breast cancer that has spread to other parts of the body) and whose disease has progressed following intravenous (i.v.) chemotherapy with anthracyclines. Xeloda monotherapy is also indicated for treatment of patients with metastatic breast cancer that is resistant to other chemotherapy drugs such as paclitaxel and anthracyclines. Xeloda is licensed for the first-line treatment of stomach cancer that has spread, in South Korea.

    About Roche
    Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2004 sales by the Pharmaceuticals Division totalled 21.7 billion Swiss francs, while the Diagnostics Division posted sales of 7.8 billion Swiss francs. Roche employs roughly 65,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai.
    All trademarks used or mentioned in this release are legally protected.

    Media Relations Contacts:
    Julia Pipe
    International Communications Manager
    Tel: 41-61-687-4376
    Email: julia.pipe@roche.com

    Further Information Available from Media Relations Contacts:References:
    1. Schmoll HJ et al. Initial safety findings from XELOXA: a randomised phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer. Abstract 617 presented at the 13th European Cancer Conference, Paris, 2005.
    2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Annals of Oncology 2005;16:481-488 3. Boyle P, Langman JS. ABC of colorectal cancer. Epidemiology. BMJ 2000;321:805-808
    4. Twelves C et al. Capecitabine as adjuvant treatment for stage III colon cancer. New Eng Journ Med 2005; vol 352: no.26: 2696-2704.
    5. Arkenau HT et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis. Proc ASCO 2005 (Abst 3507).
    6. Sastre J et al. Preliminary results of a randomized phase III trial of the TTD Group comparing Capecitabine and Oxaliplatin (CapeOx) vs. Oxaliplatin and 5-Fluorouracil in continuous infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer (CRC). Proc ASCO 2005 (Abst 3524).
    7. Hochster HS et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. Proc ASCO 2005 (Abst 3515).

    Shire Health New York

    Related Colorectal Cancer Articles from Brightsurf:

    Colorectal cancer treatment: the winning combinations
    Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

    A new model to predict survival in colorectal cancer
    This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

    Roadmap to reducing colorectal cancer deaths
    The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

    Study provides new insight on colorectal cancer growth
    A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

    Researchers ID target for colorectal cancer immunotherapy
    Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

    Colorectal cancer partner-in-crime identified
    A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

    Cancer cell reversion may offer a new approach to colorectal cancer treatment
    A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

    A novel pathway to target colorectal cancer
    Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

    Colorectal cancer rates in Canada
    The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

    Cancer drugs promote stem cell properties of colorectal cancer
    Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

    Read More: Colorectal Cancer News and Colorectal Cancer Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.